RecruitingPhase 1Phase 2NCT07388277

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

A Phase I/II Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Sponsor

Marcela V. Maus, M.D.,Ph.D.

Enrollment

12 participants

Start Date

Jul 9, 2026

Study Type

INTERVENTIONAL

Conditions

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Summary

The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CC-97540 and a drug called Lymphodepletion Chemotherapy for people with antineutrophil cytoplasmic antibody-associated vasculitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCC-97540

Intravenous infusion

DRUGLymphodepletion Chemotherapy

Intravenous infusion of cyclophosphamide and fludarabine

Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07388277

Related Trials

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

NCT0607248283 locations

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT0673393517 locations